with NOA. Then we presented a novel stopgain mutation of TACR3 gene in a patient with NOA which next-generation sequencing (NGS) indicated.
TACR3 gene encodes the receptor for the tachykinin neurokinin 3(NKR or known as NK3R), which is the endogenous receptor for neurokinin B (NKB), which is encoded by TAC3. 11 The receptors belonging to this family are characterized by interactions with G proteins and seven hydrophobic transmembrane regions. TACR3 is expressed in uterus, placenta, skeletal muscle, liver, lung, intestinal tract, and widely expressed in the central nervous system, including hypothalamic nuclei involved in regulating GnRH release. 12, 13 In the recent years, missense loss-of-function mutations inTAC3
and TACR3 have been reported in cases with nonsyndromic normosmic congenital hypogonadotropic hypogonadism (nCHH), 14 the disease which result in azoospermia at the pre-testicular (NOA) level. 15 TACR3 was considered to be one of the first two genes to be screened in a clinical setting for equivocal cases such as constitutional delay in puberty vs idiopathic HH. 16 NKB action via the NK3R plays a fundamental role in the physiology of human gonadotrope axis and this pathway is necessary for the central neuroendocrine control of human reproduction.
14,17,18
| MATERIAL S AND ME THODS
This study was approved by the Ethics Committee of the First Hospital of Jilin University. All the participants were Han Chinese.
Written informed consent was obtained after the nature of the procedures had been fully explained prior to the study. We recruited patients who consulted for sterility and diagnosed as nonobstructive azoospermia. By performing the comprehensive examinations including a detailed medical history, physical examination, chromosome analysis, Y-chromosome microdeletions, semen analysis, and hormone profiles, these patients were diagnosed as having nonobstructive azoospermia. If patients were detected with Y-chromosomal microdeletion, they were excluded by the study. Finally a total of 200 patients were recruited. They were subjected to sequencing analysis of the spermatogenesis associated genes.
Mutation screening of genes was performed by targeted exome sequencing. Genomic DNA was isolated from blood lymphocyte samples and subjected to exome capture using the in house After alignment to the human reference genome (GRCh37/hg19), most likely nondeleterious variants were filtered as previously described. 19 Variants with minor allele frequencies greater than 1%
in the databases including dbSNP, 1000 Genomes Project, Exome Aggregation Consortium, Exome Variant Server, were excluded because they were unlikely to be deleterious. Intronic variants and synonymous variants that were located within intronic regions, regulatory regions and nonregulatory intergenic regions were excluded.
Nonsynonymous variants and splice site variants were remained.
Pathogenicity of nonsynonymous variants was assessed using SIFT 
| RE SULTS
After targeted exome sequencing was performed in 200 individuals with nonobstructive azoospermia and evaluated for mutations in the 25 spermatogenesis associated genes, we examined whether TACR3 genetic defects were associated with nonobstructive azoospermia.
As a result, the present study discovered a novel stopgain mutation c.G992A (p.W331X) in a patient, in whom no variations were found in other 24 spermatogenesis associated genes. The novel mutation, which was located in the exon 4 of TACR3, was heterozygous and categorized as pathogenic. We performed PCR and Sanger sequencing on this patient and confirmed the heterozygous stopgain mutation in the patient but not in the control ( Figure 1A) . Table 1 .
| D ISCUSS I ON
Congenital hypogonadotropic hypogonadism (CHH), which result in azoospermia at the pre-testicular (NOA) level, 15 has classically been categorized as a monogenic disorder in the past few years. and TAC3 (encoding NKB) in the pathogenesis of GnRH deficiency. 18 Other investigators have also reported additional loss-of-function mutations in the genes in the cases with GnRH deficiency subsequently, which confirmed the two genes' critical role in normal reproductive development and function. 13, 14, 17, 23, 24 These facts highlight the importance of TAC3 and TACR3 in reproduction. However, the HH disease phenotype does not occur in the patient with the novel TACR3 stopgain mutation c.G992A (p.W331X) in this study. We hypothesized that the less severe affected phenotype was due to the fact that the stopgain mutation was heterozygous. The patients with 
